US 11,674,184 B2 · Enhancing radiation sensitivity comprising administering PMVK inhibiting siRNA and shRNA

Abstract

The present invention relates to a biomarker composition for diagnosing radiation-resistant cancer comprising PMVK as an active ingredient and a method of diagnosing radiation-resistant cancer using the same, and when the PMVK is knocked down, it is confirmed that the survival rate of cancer cells decreases during radiation treatment, and based on this, the possibility as a factor related to radiation therapy resistance to cancer was suggested, and the PMVK can be used as a new target to enhance the effect of radiation therapy on human cancer cells.

Claims2

Dependent claims

A method for enhancing radiation sensitivity to cancer cells comprising a step of administering to a subject in need thereof a pharmaceutical composition comprising a phosphomevalonate kinase (PMVK) protein expression inhibitor as an active ingredient,

wherein the PMVK protein expression inhibitor is a small interfering RNA (siRNA) selected from the group consisting of SEQ ID NOS:
1-3 or a short hairpin RNA (shRNA) of SEQ ID NO:
9.

Dependencies are inferred from the claim text.

Facts

Application

16/766,297Filed 21 Nov 2018

Priority

KR 10-2017-015632022 Nov 2017

Published

US 2021/0025007 A128 Jan 2021

Granted

13 Jun 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

C12Q 1/6886
For diseases caused by alterations of genetic material: for cancer
G01N 33/5752
For cancer: of the lungs
A61K 31/7105
Compounds having three or more nucleosides or nucleotides: natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine,…
A61K 38/005
Medicinal preparations containing peptides: enzyme inhibitors

Enhancing radiation sensitivity comprising administering PMVK inhibiting siRNA and shRNA

Life of this patent

Enhancing radiation sensitivity comprising administering PMVK inhibiting siRNA and shRNA

Life of this patent

Abstract

Claims2